BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors - Trial NCT06368960
Access comprehensive clinical trial information for NCT06368960 through Pure Global AI's free database. This Phase 1 trial is sponsored by InnoBM Pharmaceuticals Co., Ltd. and is currently Recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
InnoBM Pharmaceuticals Co., Ltd.
Timeline & Enrollment
Phase 1
Nov 07, 2022
Dec 31, 2024
Primary Outcome
DLT and MTD,Pharmacokinetic (PK) parameters,Number of patients with adverse events (AEs)
Summary
This is a non-randomized，open-label，controlled multi-center Phase Ⅰ study to evaluate
 tolerability, pharmacokinetics, and preliminary efficacy of BM201 injection in combination
 with radiotherapy in patients with histologically or cytologically confirmed unresectable
 locally advanced or metastatic solid tumors who have failed standard therapy or are unable to
 receive standard treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06368960
Non-Device Trial